EIP
REGN icon

Epoch Investment Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Epoch Investment Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Sell
186,850
-51,875
-22% -$35.3M 0.66% 47
2026
Q1 		$184M Sell
238,725
-42,610
-15% -$32.6M 1.12% 13
2025
Q4 		$217M Buy
281,335
+22,182
+9% +$15.1M 1.23% 11
2025
Q3 		$146M Buy
259,153
+56,096
+28% +$31.7M 0.8% 33
2025
Q2 		$107M Sell
203,057
-4,399
-2% -$2.46M 0.55% 63
2025
Q1 		$132M Buy
207,456
+10,190
+5% +$7.01M 0.68% 47
2024
Q4 		$141M Buy
197,266
+39,526
+25% +$33.2M 0.68% 42
2024
Q3 		$166M Sell
157,740
-5,556
-3% -$6.18M 0.74% 34
2024
Q2 		$172M Buy
163,296
+59,745
+58% +$57.9M 0.78% 34
2024
Q1 		$99.7M Buy
+103,551
New +$98.5M 0.44% 77

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Epoch Investment Partners's REGN Position: Q2 2026 in Review

Epoch Investment Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 22% in Q2 2026, selling an estimated $35.3M and leaving 186,850 shares worth $117M. The position accounts for 0.66% of the portfolio, ranked #47.

Epoch Investment Partners first reported a position in REGN in Q1 2024 and has held it in 10 quarters since. The position peaked at $217M in Q4 2025. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Epoch Investment Partners held 186,850 shares of Regeneron Pharmaceuticals worth $117M as of Q2 2026.
  • Epoch Investment Partners sold 51,875 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $35.3M.
  • Regeneron Pharmaceuticals made up 0.66% of Epoch Investment Partners's portfolio in Q2 2026, its #47 holding.
  • Epoch Investment Partners first reported a position in Regeneron Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
  • Epoch Investment Partners's Regeneron Pharmaceuticals position peaked at $217M in Q4 2025.
  • 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Epoch Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.